Crispr And Cas Genes Market Scope And Analysis

Report Code : TIPRE00016686
Category : Life Sciences

No. of Pages : 150

Buy Now

CRISPR and Cas Gene Market Analysis, Size, and Growth (2021-2022)

Buy Now

CRISPR and Cas Gene Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 2.78 Billion
Market Size by 2030	US$ 15.10 Billion
Global CAGR (2022 - 2030)	23.6%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Product & Service Product and Services By Application Biomedical and Agriculture By End User Biotechnology and Pharmaceutical Companies Academics and Government Research Institutes Contract Research Organizations and CDMOs
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	CRISPR Therapeutics BRAIN Biotech AG Thermo Fisher Scientific Merck KGaA Editas Medicine Takara Bio Genscript Qiagen New England Biolabs

Industry Developments and Future Opportunities:

The CRISPR and Cas gene market forecast can help stakeholders in this marketplace plan their growth strategies. A few of the strategic developments by leading market players are listed below:

In February 2023, Ensoma acquired Twelve Bio ApS to further develop its in vivo engineered cell medicines portfolio. Twelve Bio is a company engaged in exploring therapeutic applications of next-generation CRISPR-Cas drugs.
In December 2022, a researcher from the University of California started off with a clinical trial entitled “Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease” to evaluate hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9-edited red blood cells—known as CRISPR_SCD001 Drug Product).
In November 2022, researchers at the Massachusetts Institute of Technology developed a CRISPR-based PASTE tool that inserts large DNA sequences into desired cell locations. The technique can be potentially used in the treatment of various genetic diseases.
In November 2021, Health Canada approved the clinical trial application submitted by CRISPR Therapeutics and ViaCyte for VCTX210, a CRISPR-engineered stem cell therapy for treating type 1 diabetes.

Competitive Landscape and Key Companies:

CRISPR Therapeutics; Thermo Fisher Scientific; Merck; GenScript; Qiagen; Takara Bio Inc.; Brain Biotech AG; Intellia Therapeutics, Inc.; New England Biolabs; and Editas Medicine, Inc. are among the prominent companies profiled in the CRISPR and Cas gene market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.